Case report documents fatal rhabdomyolysis in ACS patient after high-dose rosuvastatin therapy, suggesting pharmacogenetic risks and drug interactions.
Key Points
Fatal rhabdomyolysis developed in a patient following a dose increase of rosuvastatin after acute coronary syndrome.
The patient experienced muscle pain and acute renal failure, resulting in death, highlighting significant risks with high-dose statin therapy.
Analysis revealed a drug-drug interaction between rosuvastatin and ticagrelor, increasing rosuvastatin concentrations up to 2.6 times.
Pharmacogenetic predisposition and monitoring are crucial to prevent adverse events in patients receiving lipid-lowering therapy.